SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (Nasdaq:CEGE) announced today that immunological data from the ongoing Phase 1 clinical trial of GVAX immunotherapy for prostate cancer in combination with ipilimumab (MDX-010) suggest an association between an increase in T-cell immunity and anti-tumor activity as measured by a decrease in prostate-specific antigen (PSA) serum levels. These data (Abstract #2538) were presented by Saskia JAM Santegoets, Ph.D., from the Department of Medical Oncology and Pathology of Vrije Universiteit Medical Center located in Amsterdam, Netherlands, at the annual meeting of the American Association for Cancer Research (AACR) being held in San Diego, California. GVAX immunotherapy for prostate cancer is an investigational product currently in development by Cell Genesys, and ipilimumab is a fully human anti-CTLA-4 antibody, an investigational product currently in development by Medarex, Inc. in partnership with Bristol-Myers Squibb Company.
